aTyr Pharma Announces Dosing Of First Patient In Phase 2 EFZO-CONNECT Study Of Efzofitimod In Patients With SSc-ILD
Portfolio Pulse from Benzinga Newsdesk
aTyr Pharma has announced the dosing of the first patient in its Phase 2 EFZO-CONNECT study. The study will evaluate the efficacy, safety, and tolerability of efzofitimod, a first-in-class biologic immunomodulator, in patients with systemic sclerosis-related interstitial lung disease. The drug has been granted U.S. FDA and EU orphan drug and U.S. FDA Fast Track designations for systemic sclerosis. The study is a 28-week study with three parallel cohorts randomized to either 270 mg or 450 mg of efzofitimod or placebo dosed intravenously monthly for a total of 6 doses.
October 31, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
aTyr Pharma's initiation of the Phase 2 EFZO-CONNECT study could potentially lead to positive outcomes for the company if the study results are successful.
The initiation of the Phase 2 study is a significant step for aTyr Pharma. If the study results are positive, it could lead to the approval of the drug, which would be a significant boost for the company. However, the results of the study are not yet known, so there is still some uncertainty.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100